ORIC Pharmaceuticals Inc
ORIC
Company Profile
Business description
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Contact
240 E. Grand Avenue
2nd Floor
South San FranciscoCA94080
USAT: +1 650 388-5600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
111
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
stocks
Surge in combat drones drives upgrade for ASX share
Drone demand powers growth but investor optimism is overdone.
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
The market’s negative reaction to the announcement signals that investors, much like us, are not super excited about Meta’s prospects in the enterprise market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,854.70 | 60.30 | 0.69% |
| CAC 40 | 7,884.03 | 48.72 | 0.62% |
| DAX 40 | 25,230.93 | 291.58 | 1.17% |
| Dow JONES (US) | 50,926.56 | 20.51 | 0.04% |
| FTSE 100 | 10,463.24 | 34.97 | 0.34% |
| HKSE | 23,972.29 | 640.98 | -2.60% |
| NASDAQ | 26,871.60 | 10.53 | 0.04% |
| Nikkei 225 | 68,309.46 | 647.26 | -0.94% |
| NZX 50 Index | 13,680.49 | 130.02 | -0.94% |
| S&P 500 | 7,666.45 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,682.10 | 67.70 | 0.79% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |